SEHK:3933Pharmaceuticals
A Look At United Laboratories International Holdings (SEHK:3933) Valuation After Positive UBT251 Phase II Obesity Trial Results
United Laboratories International Holdings (SEHK:3933) and Novo Nordisk have reported Phase 2 data for obesity drug UBT251 in China, with plans to move into Phase 3 locally and to expand global studies.
See our latest analysis for United Laboratories International Holdings.
The Phase 2 obesity data arrives at a time when the share price has a HK$12.63 latest close and a 3 year total shareholder return above 200%. However, the 1 year total shareholder return of about a 5% decline suggests...